Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19
INTRODUCTION: Chlorpromazine has been suggested as being potentially useful in patients with coronavirus disease 2019 (COVID-19) on the grounds of its potential antiviral and anti-inflammatory effects.
OBJECTIVE: The aim of this study was to examine the association between chlorpromazine use and mortality among adult patients hospitalized for COVID-19.
METHODS: We conducted an observational, multicenter, retrospective study at Assistance Publique-Hôpitaux de Paris (AP-HP) Greater Paris University hospitals. Study baseline was defined as the date of first prescription of chlorpromazine during hospitalization for COVID-19. The primary endpoint was death. Among patients who had not been hospitalized in intensive care units (ICUs), we compared this endpoint between those who received chlorpromazine and those who did not, in time-to-event analyses adjusted for patient characteristics, clinical markers of disease severity, and other psychotropic medications. The primary analysis used a Cox regression model with inverse probability weighting. Multiple sensitivity analyses were performed.
RESULTS: Of the 14,340 adult inpatients hospitalized outside ICUs for COVID-19, 55 patients (0.4%) received chlorpromazine. Over a mean follow-up of 14.3 days (standard deviation [SD] 18.2), death occurred in 13 patients (23.6%) who received chlorpromazine and 1289 patients (9.0%) who did not. In the primary analysis, there was no significant association between chlorpromazine use and mortality (hazard ratio [HR] 2.01, 95% confidence interval [CI] 0.75-5.40; p = 0.163). Sensitivity analyses included a Cox regression in a 1:5 ratio matched analytic sample that showed a similar result (HR 1.67, 95% CI 0.91-3.06; p = 0.100) and a multivariable Cox regression that indicated a significant positive association (HR 3.10, 95% CI 1.31-7.34; p = 0.010).
CONCLUSION: Our results suggest that chlorpromazine prescribed at a mean daily dose of 70.8 mg (SD 65.3) was not associated with reduced mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Clinical drug investigation - 41(2021), 3 vom: 09. März, Seite 221-233 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hoertel, Nicolas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chlorpromazine |
|---|
| Anmerkungen: |
Date Completed 06.04.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40261-021-01001-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321201949 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321201949 | ||
| 003 | DE-627 | ||
| 005 | 20231225175316.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40261-021-01001-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1070.xml |
| 035 | |a (DE-627)NLM321201949 | ||
| 035 | |a (NLM)33559821 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hoertel, Nicolas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.04.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Chlorpromazine has been suggested as being potentially useful in patients with coronavirus disease 2019 (COVID-19) on the grounds of its potential antiviral and anti-inflammatory effects | ||
| 520 | |a OBJECTIVE: The aim of this study was to examine the association between chlorpromazine use and mortality among adult patients hospitalized for COVID-19 | ||
| 520 | |a METHODS: We conducted an observational, multicenter, retrospective study at Assistance Publique-Hôpitaux de Paris (AP-HP) Greater Paris University hospitals. Study baseline was defined as the date of first prescription of chlorpromazine during hospitalization for COVID-19. The primary endpoint was death. Among patients who had not been hospitalized in intensive care units (ICUs), we compared this endpoint between those who received chlorpromazine and those who did not, in time-to-event analyses adjusted for patient characteristics, clinical markers of disease severity, and other psychotropic medications. The primary analysis used a Cox regression model with inverse probability weighting. Multiple sensitivity analyses were performed | ||
| 520 | |a RESULTS: Of the 14,340 adult inpatients hospitalized outside ICUs for COVID-19, 55 patients (0.4%) received chlorpromazine. Over a mean follow-up of 14.3 days (standard deviation [SD] 18.2), death occurred in 13 patients (23.6%) who received chlorpromazine and 1289 patients (9.0%) who did not. In the primary analysis, there was no significant association between chlorpromazine use and mortality (hazard ratio [HR] 2.01, 95% confidence interval [CI] 0.75-5.40; p = 0.163). Sensitivity analyses included a Cox regression in a 1:5 ratio matched analytic sample that showed a similar result (HR 1.67, 95% CI 0.91-3.06; p = 0.100) and a multivariable Cox regression that indicated a significant positive association (HR 3.10, 95% CI 1.31-7.34; p = 0.010) | ||
| 520 | |a CONCLUSION: Our results suggest that chlorpromazine prescribed at a mean daily dose of 70.8 mg (SD 65.3) was not associated with reduced mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Chlorpromazine |2 NLM | |
| 650 | 7 | |a U42B7VYA4P |2 NLM | |
| 700 | 1 | |a Sánchez-Rico, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Vernet, Raphaël |e verfasserin |4 aut | |
| 700 | 1 | |a Jannot, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Neuraz, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Lemogne, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Airagnes, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Paris, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Daniel, Christel |e verfasserin |4 aut | |
| 700 | 1 | |a Gramfort, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Lemaitre, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Bernaux, Mélodie |e verfasserin |4 aut | |
| 700 | 1 | |a Bellamine, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Beeker, Nathanaël |e verfasserin |4 aut | |
| 700 | 1 | |a Limosin, Frédéric |e verfasserin |4 aut | |
| 700 | 0 | |a AP-HP/Universities/INSERM COVID-19 Research Collaboration and AP-HP COVID CDR Initiative |e verfasserin |4 aut | |
| 700 | 1 | |a Ancel, Pierre-Yves |e investigator |4 oth | |
| 700 | 1 | |a Bauchet, Alain |e investigator |4 oth | |
| 700 | 1 | |a Beeker, Nathanaël |e investigator |4 oth | |
| 700 | 1 | |a Benoit, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Bernaux, Mélodie |e investigator |4 oth | |
| 700 | 1 | |a Bellamine, Ali |e investigator |4 oth | |
| 700 | 1 | |a Bey, Romain |e investigator |4 oth | |
| 700 | 1 | |a Bourmaud, Aurélie |e investigator |4 oth | |
| 700 | 1 | |a Breant, Stéphane |e investigator |4 oth | |
| 700 | 1 | |a Burgun, Anita |e investigator |4 oth | |
| 700 | 1 | |a Carrat, Fabrice |e investigator |4 oth | |
| 700 | 1 | |a Caucheteux, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Champ, Julien |e investigator |4 oth | |
| 700 | 1 | |a Cormont, Sylvie |e investigator |4 oth | |
| 700 | 1 | |a Daniel, Christel |e investigator |4 oth | |
| 700 | 1 | |a Dubiel, Julien |e investigator |4 oth | |
| 700 | 1 | |a Ducloas, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Esteve, Loic |e investigator |4 oth | |
| 700 | 1 | |a Frank, Marie |e investigator |4 oth | |
| 700 | 1 | |a Garcelon, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Gramfort, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Griffon, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Grisel, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Guilbaud, Martin |e investigator |4 oth | |
| 700 | 1 | |a Hassen-Khodja, Claire |e investigator |4 oth | |
| 700 | 1 | |a Hemery, François |e investigator |4 oth | |
| 700 | 1 | |a Hilka, Martin |e investigator |4 oth | |
| 700 | 1 | |a Jannot, Anne Sophie |e investigator |4 oth | |
| 700 | 1 | |a Lambert, Jerome |e investigator |4 oth | |
| 700 | 1 | |a Layese, Richard |e investigator |4 oth | |
| 700 | 1 | |a Leblanc, Judith |e investigator |4 oth | |
| 700 | 1 | |a Lebouter, Léo |e investigator |4 oth | |
| 700 | 1 | |a Lemaitre, Guillaume |e investigator |4 oth | |
| 700 | 1 | |a Leprovost, Damien |e investigator |4 oth | |
| 700 | 1 | |a Lerner, Ivan |e investigator |4 oth | |
| 700 | 1 | |a Sallah, Kankoe Levi |e investigator |4 oth | |
| 700 | 1 | |a Maire, Aurélien |e investigator |4 oth | |
| 700 | 1 | |a Mamzer, Marie-France |e investigator |4 oth | |
| 700 | 1 | |a Martel, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Mensch, Arthur |e investigator |4 oth | |
| 700 | 1 | |a Moreau, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Neuraz, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Orlova, Nina |e investigator |4 oth | |
| 700 | 1 | |a Paris, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Rance, Bastien |e investigator |4 oth | |
| 700 | 1 | |a Ravera, Hélène |e investigator |4 oth | |
| 700 | 1 | |a Rozes, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Salamanca, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Sandrin, Arnaud |e investigator |4 oth | |
| 700 | 1 | |a Serre, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Tannier, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Treluyer, Jean-Marc |e investigator |4 oth | |
| 700 | 1 | |a van Gysel, Damien |e investigator |4 oth | |
| 700 | 1 | |a Varoquaux, Gaël |e investigator |4 oth | |
| 700 | 1 | |a Vie, Jill Jen |e investigator |4 oth | |
| 700 | 1 | |a Wack, Maxime |e investigator |4 oth | |
| 700 | 1 | |a Wajsburt, Perceval |e investigator |4 oth | |
| 700 | 1 | |a Wassermann, Demian |e investigator |4 oth | |
| 700 | 1 | |a Zapletal, Eric |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical drug investigation |d 1995 |g 41(2021), 3 vom: 09. März, Seite 221-233 |w (DE-627)NLM094465762 |x 1179-1918 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:3 |g day:09 |g month:03 |g pages:221-233 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40261-021-01001-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 3 |b 09 |c 03 |h 221-233 | ||